Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
about
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusA randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy.Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes.The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.SGLT2 Inhibition in a Kidney with Reduced Nephron Number: Modeling and Analysis of Solute Transport and Metabolism.Sweet Success? SGLT2 Inhibitors and Diabetes.SGLT2 inhibitors: are they safe?Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
P2860
Q33696974-5DE93C24-2C96-4006-A684-5C6AD76482E7Q33871321-31AAA503-87F6-47EB-8D4F-067F9C5037AFQ33913060-4EFAB3C0-13BD-4515-A812-BC2057B60D8BQ37559907-35292155-9416-4FE7-ACEE-68108A2B1EAEQ38775305-26CE5555-7675-487D-93B3-FE17A81C909CQ38927264-BEBB7A34-41CB-43B3-A370-86274750E15EQ39300236-7F496FB2-A198-40BB-80E6-081970D1A30FQ40799248-27A37DC9-2F80-47D3-8BBA-88B3F8458BA2Q47109331-A2D82F7F-8370-434F-AB5E-51DBCC4E5254Q47110037-2614BEB2-70A9-4C14-8E06-ACE1C77D854DQ47557423-49F629FE-8BEA-4D64-BA8F-3FF91228A402Q47557951-E9864AE5-BC75-4A5A-936F-D6B47838BC86Q47642298-0FE58421-72C2-4301-9E39-C550846BD2F2Q50100476-FEB3C632-4EC3-48CF-9C67-8A9EE5732B4FQ51733588-5C5F6DFC-7977-4C49-AB60-9EB4CABE8139Q51746289-F49B12CB-CE9E-4447-A9F0-E652201F3602Q52562709-1EAF8380-B8F0-4CF7-B611-5F1317D57DF9Q52598205-751F84A7-8C13-4937-9340-C14A6E0C8622Q52724494-AA68FA5F-AC4B-4B77-8C62-CFE6B7A9DAA7Q55053753-6CECBC01-CFF0-4E1F-B6C0-A3F4A41AC025Q55262124-80494DD8-52EF-46F8-B7D9-733FC18D278AQ55332339-5059D054-1F46-4F91-B91F-CF1388452F56Q55411384-22CCD8C0-ACC1-4C7B-A9E2-6A8CFCCB6149Q57136996-9D3339D7-CC67-4173-8892-8EA284F1405B
P2860
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@ast
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@en
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@nl
type
label
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@ast
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@en
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@nl
prefLabel
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@ast
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@en
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@nl
P2093
P2860
P3181
P356
P1476
Increased Hematocrit During So ...... l Function in Diabetic Kidneys
@en
P2093
Makoto Takei
Motoaki Sano
Yasuyuki Shiraishi
Yoshihiko Suzuki
P2860
P304
P3181
P356
10.14740/JOCMR2760W
P407
P577
2016-12-01T00:00:00Z